Subscribe to RSS
Please copy the URL and add it into your RSS Feed Reader.
https://www.thieme-connect.de/rss/thieme/en/10.1055-s-00035024.xml
Download PDF
Thromb Haemost 2015; 113(06): 1381-1382
DOI: 10.1160/TH14-12-1055
DOI: 10.1160/TH14-12-1055
Letters to the Editor
Clinical utility of screening for CALR gene exon 9 mutations in patients with splanchnic venous thrombosis
Authors
Further Information
Publication History
Received:
18 December 2014
Accepted after major revision:
16 January 2015
Publication Date:
18 November 2017 (online)
-
References
- 1 Dentali F, Squizzato A, Brivio L. et al. JAK2V617F mutation for the early diagnosis of Ph-myeloproliferative neoplasms in patients with venous thromboembolism: a meta-analysis myeloproliferative neoplasms in patients with venous thromboembolism: a meta-analysis. Blood 2009; 113: 5617-5623.
- 2 Smalberg JH, Arends LR, Valla DC. et al. Myeloproliferative neoplasms in Budd-Chiari syndrome and portal vein thrombosis: a meta-analysis. Blood 2012; 120: 4921-4928.
- 3 De Stefano V, Fiorini A, Rossi E. et al. Incidence of the JAK2 V617F mutation among patients with splanchnic or cerebral venous thrombosis and without overt chronic myeloproliferative disorders. J Thromb Haemost 2007; 05: 708-714.
- 4 Primignani M, Barosi G, Bergamaschi G, et al. Role of the JAK2 mutation in the diagnosis of chronic myeloproliferative disorders in splanchnic vein thrombosis. Hepatology 2006; 44: 1528-1534.
- 5 Colaizzo D, Amitrano L, Tiscia GL. et al. The JAK2 V617F mutation frequently occurs in patients with portal and mesenteric venous thrombosis. J Thromb Haemost 2007; 05: 55-61.
- 6 Klampfl T, Gisslinger H, Harutyunyan AS, et al. Somatic mutations of calreticulin in myeloproliferative neoplasms. N Engl J Med 2013; 369: 2379-2390.
- 7 Nangalia J, Massie CE, Baxter EJ. et al. Somatic CALR mutations in myeloproliferative neoplasms with nonmutated JAK 2. N Engl J Med 2013; 369: 2391-2405.
- 8 Broséus J, Park JH, Carillo S. et al. Presence of calreticulin mutations in JAK2-negative polycythemia vera. Blood 2014; 124: 3964-3966.
- 9 Rotunno G, Mannarelli C, Guglielmelli P. et al. Impact of calreticulin mutations on clinical and hematological phenotype and outcome in essential thrombocythemia. Blood 2014; 123: 1552-1555.
- 10 Rumi E, Pietra D, Ferretti V. et al. JAK2 or CALR mutation status defines subtypes of essential thrombocythemia with substantially different clinical course and outcomes. Blood 2014; 123: 1544-1551.
- 11 Xavier S, Gadelha T, Rezende SM, et al. JAK2V617F mutation in patients with thrombosis: to screen or not to screen?. Int J Lab Hematol 2011; 33: 117-124.
- 12 Condat B, Valla D. Nonmalignant portal vein thrombosis in adults. Nat Clin Pract Gastroenterol Hepatol 2006; 09: 505-515.
- 13 Baxter EJ, Scott LM, Campbell PJ. et al. Acquired mutation of the tyrosine kinase JAK2 in human myeloproliferative disorders. Lancet 2005; 365: 1054-1061.
- 14 Colaizzo D, Amitrano L, Iannaccone L. et al. Gainof-function gene mutations and venous thromboembolism: distinct roles in different clinical settings. J Med Genet 2007; 44: 412-416.
- 15 Turon F, Cervantes F, Colomer D. et al. Role of calreticulin mutations in the aetiological diagnosis of splanchnic vein thrombosis. J Hepatol 2015; 62: 72-74.
- 16 Haslam K, Langabeer SE. Incidence of CALR mutations in patients with splanchnic vein thrombosis. Br J Haematol. 2014. Epub ahead of print
- 17 Roques M, Park JH, Minello A. et al. Detection of the CALR mutation in the diagnosis of splanchnic vein thrombosis. Br J Haematol. 2014. Epub ahead of print
- 18 Iurlo A, Cattaneo D, Gianelli U. et al. Molecular analyses in the diagnosis of myeloproliferative neoplasm-related splanchnic vein thrombosis. Ann Hematol. 2014. Epub ahead of print.